Clinical significance of CD45RO expression on peripheral blood mononuclear cells in HTLV‐I‐infected individuals

Abstract

The phenotype of peripheral blood mononuclear cells (PBMC) was examined in 13 healthy volunteers, 26 HTLV-I carriers, and 58 ATL patients (22 smouldering, five chronic, 24 acute, and seven lymphoma type). The percentage of CD4+, CD25+, CD28+ and CD45RO+ cells in the PBMC of the chronic and acute type patients was significantly higher than that of the volunteers, whereas the percentage of CD8+ and CD45RA+ cells in these patients was significantly low. The histogram for CD45RO fluorescence intensity (FI) revealed two patterns: pattern A consisted of CD45RO+ cells with high FI (CD45ROhigh) and intermediate FI (CD45ROint). Pattern B consisted exclusively of CD45ROhigh. Pattern A was evident in all volunteers. The percentage of subjects showing pattern B was increased in an order that reflected disease progression. In the patients with pattern A, the CD45ROint cells were CD4+ and CD8-, and the FI of CD2, CD3, and Fas within the CD45ROint cells appeared to be lower than that within the CD45ROhigh cells. The acute type patients with pattern A had a significantly longer survival curve than that of these patients with pattern B. These results suggest that the presence of CD45ROint cells may be related to protection against disease progression in HTLV-I-infected individuals.

Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia

“…Since it is reported that ATL cells belong to CD4 ϩ , CD8 Ϫ , and CD45RO ϩ cells, 23 we used CD4 ϩ and CD4 ϩ CD45RO ϩ T cells in peripheral blood from healthy volunteers as controls. Although ATL is a relatively rare disease, we collected leukemia cells from 8 patients with acute ATL and compared them with 5 samples of CD4 ϩ and 3 samples of CD4 ϩ CD45RO ϩ T cell subsets.…”

T helper cell activation and human retroviral pathogenesis.

“…In addition, HTLV-1infected individuals with ATL have been reported to undergo a spontaneous remission which was paralleled by a decrease in CD45RO expression by PBMC (318). In another study, the CD45RO cell populations in HTLV-1 carriers and infected individuals with ATL were examined (319). This study found two patterns of CD45RO expression.…”

“…The intermediate-intensity population expressed far lower levels of Fas antigen than did the high-intensity cells, further VOL. 60,1996 Th-CELL ACTIVATION AND RETROVIRAL PATHOGENESIS suggesting that intermediate-intensity CD45RO cells may be protective against apoptosis and disease progression (319). Virus-mediated inhibition of apoptosis has been observed for adenovirus (280), Epstein-Barr virus, (139), and Sindbis virus (203).…”

Flow Cytometric Immunophenotyping of Adult T-Cell Leukemia/Lymphoma Using CD3 Gating

“…10 The expression of CD2, CD3, CD4, CD8, CD25, CD28, CD45RA, CD45RO, and HLA-DR on ATLL cells has been reported, but these data are based on immunophenotyping combined with flow cytometric analysis using a conventional gating step for forward scatter and SS or on immunohistochemical analysis. [12][13][14][15][16] Flow cytometric analysis has been introduced to study hematologic malignancy based on surface antigen levels, because malignant cells often display an aberrant phenotype, which may involve antigen loss or changes in combinations of surface markers, compared with normal hematologic cells. However, most T-cell antigens are expressed on normal and abnormal T lymphocytes.…”

“…10,11 Immunophenotyping performed by flow cytometric analysis with CD3 low gating is largely consistent with the immunophenotyping criteria suggested in the REAL classification, 10 as previous reports also have stated. [12][13][14][15][16] We studied the immunophenotyping of ATLL by flow cytometric analysis with CD3 gating. Because statistically significant differences in immunophenotyping were apparent between CD3 low and CD3 medium gating, we compared the results * ✝ ✝ ❚Figure 2❚ There was no significant difference in the expression of CD2, CD4, CD5, CD28, CD62L, CD45RA, CD45RO, and HLA-DR.…”